A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse is a PHASE2 clinical asset sponsored by Morphotek in Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms. SEO and diligence focus: Farletuzumab, Chemo Plus Far, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.